Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver save search
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
SGMT | News | $4.28 6.2% 5.62% 360K
|
Health Technology
|
| O: 5.29%
H: 0.0%
C: -3.59%
day liver fibrosis
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
OABI | News | $4.64 -0.86% -0.86% 370K
|
|
| O: -1.58%
H: 1.77%
C: -0.4%
drug liver disease antibody for
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
CANF | $1.97 -0.51% 0.0% 3.8K
|
Health Technology
|
| O: 4.76%
H: 0.45%
C: -5.91%
drug candidate liver cancer treat namodenoson advanced
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
ONVO | $1.0 -2.91% -1.48% 120K
|
Health Technology
|
| O: 64.34%
H: 4.82%
C: -18.67%
fxr314 metabolic liver positive for results
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
MDGL | $218.38 2.29% 2.15% 350K
|
Health Technology
|
| O: 2.12%
H: 0.7%
C: -0.82%
liver treatment fibrosis pharmaceuticals for advanced nash
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
Published: 2024-04-08 (Crawled : 17:00) - globenewswire.com
INKT | $0.871 -2.57% 2.19% 97K
|
|
| O: 1.28%
H: 0.0%
C: -16.46%
nk-215 liver cancer preclinical therapeutics
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Published: 2024-04-01 (Crawled : 12:30) - globenewswire.com
SRZN | $9.01 -2.6% -0.33% 2.3K
|
|
| O: -8.98%
H: 4.61%
C: -29.37%
szn-043 liver
Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200, a Novel, First-in-Class Checkpoint Modifier Immunotherapy for Chronic Hepatitis B Virus Functional Cure, Presented as Late-Breaker at 2024 APASL Global Liver Meeting
Published: 2024-03-28 (Crawled : 00:00) - prnewswire.com
OCEA | $1.48 -1.66% -1.69% 160K
|
|
| O: 0.49%
H: 0.0%
C: -7.23%
vron-0200 hepatitis liver global immunotherapy meeting virus study
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
Published: 2024-03-15 (Crawled : 13:00) - prnewswire.com
GLMD | $0.3614 -0.74% -0.41% 65K
|
Health Technology
|
| O: 17.48%
H: 0.0%
C: -25.59%
mgl-3196 patent liver treatment fibrosis grant aramchol nash
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
Published: 2024-03-14 (Crawled : 20:00) - globenewswire.com
MDGL | $218.38 2.29% 2.15% 350K
|
Health Technology
|
| O: 20.66%
H: 2.07%
C: -8.01%
fda liver approval treatment fibrosis pharmaceuticals advanced
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
CANF | $1.97 -0.51% 0.0% 3.8K
|
Health Technology
|
| O: -0.45%
H: 2.27%
C: 2.27%
europe liver conference distribution pancreatic treatment namodenoson
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
Published: 2024-03-06 (Crawled : 14:00) - globenewswire.com
INKT | $0.871 -2.57% 2.19% 97K
|
|
| O: 1.02%
H: 0.48%
C: -1.41%
nk-215 liver cancer preclinical
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model
Published: 2024-03-06 (Crawled : 14:00) - biospace.com/
INKT | $0.871 -2.57% 2.19% 97K
|
|
| O: 1.02%
H: 0.48%
C: -1.41%
nk-215 liver cancer tumor preclinical
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
MDGL | $218.38 2.29% 2.15% 350K
|
Health Technology
|
| O: -0.86%
H: 2.04%
C: 1.66%
liver authorization treatment fibrosis pharmaceuticals ema application
Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting
Published: 2024-02-29 (Crawled : 13:00) - globenewswire.com
OCEA | $1.48 -1.66% -1.69% 160K
|
|
| O: 2.6%
H: 36.71%
C: 11.39%
first liver presentation global meeting therapeutics study
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Published: 2024-02-26 (Crawled : 07:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
pharma liver disease fibrosis trial results
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
Published: 2024-02-20 (Crawled : 15:30) - biospace.com/
BTTX | $0.006 -1.64% -65.02% 340K
|
|
| O: 7.55%
H: 2.13%
C: -27.83%
fda device liver disease designation therapeutics advanced platform
Nanox Receives FDA Clearance for HealthFLD, an Advanced AI-Based Software Empowering Clinicians in Assessment of Fatty Liver
Published: 2024-02-13 (Crawled : 13:00) - globenewswire.com
NNOX | News | $9.31 3.22% 2.91% 850K
|
Health Technology
|
| O: -6.78%
H: 2.42%
C: -3.55%
fda liver software clearance advanced
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | News | $9.49 -0.42% -1.11% 480K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | News | $169.54 0.98% 0.18% 3.2M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
GILD | $67.03 0.12% 0.12% 3.6M
|
Health Technology
|
| O: 0.32%
H: 0.11%
C: -1.55%
ALNY | $146.07 0.19% 0.18% 540K
|
Health Technology
|
| O: -2.63%
H: 0.98%
C: -1.75%
liver disease therapeutics market
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Published: 2024-02-12 (Crawled : 14:30) - biospace.com/
GILD | $67.03 0.12% 0.12% 3.6M
|
Health Technology
|
| O: -0.35%
H: 2.36%
C: 1.42%
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: 27.92%
H: 0.97%
C: 0.88%
liver acquisition sciences therapeutics
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.